X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-05-19 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.92 | +1,700 | 293,266 | +1% | +$1,570 | |||||
| D | 2026-05-19 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale+OE | $154.33 | -245,088 | 511,293 | -32% | -$37,824,872 | |||||
| M | 2026-05-19 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.96 | +4,798 | 7,740,958 | 0% | +$119,776 | |||||
2026-05-20 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $1.88 | -25,590 | 628,155 | -4% | -$48,084 | ||||||
2026-05-20 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $1.88 | -28,946 | 635,762 | -4% | -$54,482 | ||||||
| D | 2026-05-20 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $32.00 | -6,000 | 136,731 | -4% | -$192,000 | |||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Raymon Heather | SVP, Research, Development | S - Sale | $9.01 | -3,095 | 148,228 | -2% | -$27,879 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | S - Sale | $9.01 | -7,002 | 293,450 | -2% | -$63,073 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | S - Sale | $9.01 | -8,790 | 337,920 | -3% | -$79,179 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale | $9.01 | -7,037 | 144,963 | -5% | -$63,386 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $9.01 | -27,116 | 1,535,082 | -2% | -$244,253 | ||||||
2026-05-19 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $9.17 | -62,000 | 1,387,695 | -4% | -$568,540 | ||||||
2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.79 | -3,390 | 440,014 | -1% | -$2,690 | ||||||
2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.79 | -3,121 | 215,497 | -1% | -$2,477 | ||||||
2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.79 | -1,485 | 118,267 | -1% | -$1,178 | ||||||
2026-05-18 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale | $50.00 | -34,901 | 955,040 | -4% | -$1,745,050 | ||||||
2026-05-18 | EXEL | Exelixis, Inc. | Hefti Brenda | SVP, GC | S - Sale | $50.21 | -6,625 | 112,289 | -6% | -$332,641 | ||||||
2026-05-19 | ACOG | Alpha Cognition Inc. | D'Angelo Lauren | COO | P - Purchase | $5.76 | +3,500 | 140,695 | +3% | +$20,160 | ||||||
2026-05-18 | BCRX | Biocryst Pharmaceuticals Inc | McKee Amy E | Dir | S - Sale | $8.97 | -11,180 | 31,252 | -26% | -$100,285 | ||||||
| M | 2026-05-15 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.76 | +34,043 | 2,595,993 | +1% | +$196,009 | |||||
2026-05-18 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.92 | +5,700 | 291,566 | +2% | +$5,244 | ||||||
| D | 2026-05-15 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale+OE | $157.65 | -15,000 | 34,480 | -30% | -$2,364,761 | |||||
2026-05-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $132.27 | -3,000 | 173,191 | -2% | -$396,810 | ||||||
| D | 2026-05-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale+OE | $131.29 | -28,000 | 125,779 | -18% | -$3,676,199 | |||||
2026-05-15 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.00 | -1,938 | 412,074 | 0% | -$50,388 | ||||||
| D | 2026-05-14 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $26.22 | -15,000 | 0 | -100% | -$393,354 | |||||
| D | 2026-05-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $48.40 | -53,336 | 1,634,046 | -3% | -$2,581,462 | |||||
2026-05-14 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $1.20 | +300,000 | 522,497 | +135% | +$360,000 | ||||||
2026-05-13 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $82.09 | -20,000 | 1,115,987 | -2% | -$1,641,711 | ||||||
2026-05-15 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.02 | +5,100 | 285,866 | +2% | +$5,202 | ||||||
| D | 2026-05-13 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale+OE | $9.54 | -62,500 | 400,703 | -13% | -$596,250 | |||||
| D | 2026-05-13 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $32.83 | -7,000 | 18,300 | -28% | -$229,775 | |||||
2026-05-14 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $12.86 | -17,717 | 195,178 | -8% | -$227,841 | ||||||
2026-05-12 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.90 | +6,387 | 7,736,160 | 0% | +$159,036 | ||||||
2026-05-12 | NBIX | Neurocrine Biosciences Inc | Norwalk Leslie V | Dir | S - Sale | $155.01 | -3,810 | 2,429 | -61% | -$590,601 | ||||||
| D | 2026-05-12 | TWST | Twist Bioscience Corp | Johannessen Jan | Dir | S - Sale+OE | $56.12 | -12,000 | 17,754 | -40% | -$673,440 | |||||
2026-05-13 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $1.19 | +100,000 | 222,497 | +82% | +$119,000 | ||||||
2026-05-12 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | P - Purchase | $8.01 | +12,500 | 606,591 | +2% | +$100,125 | ||||||
| DM | 2026-05-11 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $68.68 | -50,000 | 767,780 | -6% | -$3,433,875 | |||||
| D | 2026-05-11 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $11.52 | +6,510,416 | 16,363,718 | +66% | +$74,999,992 | |||||
2026-05-11 | RGNX | Regenxbio Inc. | Pakola Steve | Chief Medical Officer | S - Sale | $11.02 | -15,309 | 232,617 | -6% | -$168,705 | ||||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Tpg Gp A, LLC | Former 10% Owner | P - Purchase | $18.00 | +1,388,889 | 3,690,146 | +60% | +$25,000,002 | |||||
2026-05-11 | VCEL | Vericel Corp | Wotton Paul K | Dir | S - Sale | $32.74 | -10,000 | 18,802 | -35% | -$327,425 | ||||||
2026-05-12 | XFOR | X4 Pharmaceuticals, Inc | Kirske David | CFO | S - Sale | $4.29 | -16,961 | 176,293 | -9% | -$72,820 | ||||||
| D | 2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Dimension Capital Ii, L.P. | Dir | P - Purchase | $18.00 | +1,111,111 | 3,333,516 | +50% | +$19,999,998 | |||||
2026-05-11 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | P - Purchase | $8.01 | +12,500 | 594,091 | +2% | +$100,125 | ||||||
| D | 2026-05-11 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $7.04 | -8,346 | 63,077 | -12% | -$58,756 | |||||
2026-05-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $56.88 | -4,961 | 49,674 | -9% | -$282,187 | ||||||
| D | 2026-05-08 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $48.28 | -6,636 | 2,880 | -70% | -$320,386 | |||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC | 10% | S - Sale+OE | $18.00 | -1,780 | 3,794,883 | 0% | -$32,040 | |||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC | 10% | P - Purchase | $18.00 | +555,555 | 3,794,883 | +17% | +$9,999,990 | |||||
| D | 2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Leiden Jeffrey M | Dir | P - Purchase | $20.00 | +5,000 | 301,842 | +2% | +$100,000 | |||||
2026-05-08 | ODTX | Odyssey Therapeutics, Inc. | Haas Jason | CFO | P - Purchase | $20.00 | +1,000 | 62,908 | +2% | +$20,000 | ||||||
| D | 2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Li Nan (Ln) | Dir | P - Purchase | $18.00 | +1,111,111 | 3,333,516 | +50% | +$19,999,998 | |||||
2026-05-11 | ODTX | Odyssey Therapeutics, Inc. | Chu Shelley | Dir | P - Purchase | $18.00 | +11,111 | 11,111 | New | +$199,998 | ||||||
2026-05-07 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | S - Sale | $10.10 | -313,446 | 1,318,894 | -19% | -$3,165,021 | ||||||
| M | 2026-05-07 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.75 | +51,258 | 7,729,773 | +1% | +$1,268,594 | |||||
2026-05-07 | ATRA | Atara Biotherapeutics, Inc. | Ecor1 Capital, LLC | 10% | P - Purchase | $9.35 | +507,407 | 1,552,000 | +49% | +$4,744,255 | ||||||
| D | 2026-05-11 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Dir | S - Sale+OE | $87.00 | -3,000 | 0 | -100% | -$261,000 | |||||
2026-05-07 | AURA | Aura Biosciences, Inc. | Matrix Capital Management Company, LP | 10% | S - Sale | $5.64 | -6,922,870 | 0 | -100% | -$39,044,987 | ||||||
| D | 2026-05-06 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $84.14 | -5,500 | 207,023 | -3% | -$462,784 | |||||
| D | 2026-05-07 | EXEL | Exelixis, Inc. | Beckerle Mary C | Dir | S - Sale+OE | $48.45 | -7,712 | 17,524 | -31% | -$373,646 | |||||
| D | 2026-05-07 | EXEL | Exelixis, Inc. | Freire Maria C | Dir | S - Sale+OE | $46.00 | -20,634 | 100,819 | -17% | -$949,164 | |||||
2026-05-07 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale | $45.71 | -60,000 | 118,832 | -34% | -$2,742,600 | ||||||
| D | 2026-05-07 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.37 | -40,000 | 906,556 | -4% | -$134,800 | |||||
2026-05-07 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale | $40.50 | -5,000 | 21,009 | -19% | -$202,500 | ||||||
| M | 2026-05-06 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale | $38.73 | -4,855 | 1,118 | -81% | -$188,045 | |||||
2026-05-05 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.52 | -30,000 | 6,199,863 | 0% | -$105,600 | ||||||
| DM | 2026-05-04 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $18.39 | +2,840,429 | 6,314,525 | +82% | +$52,222,946 | |||||
2026-05-04 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.34 | -264 | 506,997 | 0% | -$618 | ||||||
2026-05-04 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Chief Medical Officer | S - Sale | $30.00 | -1,065 | 67,682 | -2% | -$31,950 | ||||||
| D | 2026-05-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $14.62 | -8,000 | 166,844 | -5% | -$116,996 | |||||
2026-05-04 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $57.15 | -1,962 | 135,941 | -1% | -$112,126 | ||||||
| D | 2026-05-04 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $57.15 | -5,127 | 853,760 | -1% | -$293,002 | |||||
2026-05-04 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $57.15 | -1,116 | 122,988 | -1% | -$63,778 | ||||||
2026-05-04 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $57.15 | -2,844 | 278,964 | -1% | -$162,531 | ||||||
2026-05-04 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $57.15 | -164 | 54,635 | 0% | -$9,372 | ||||||
2026-05-04 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale | $323.73 | -1,237 | 7,115 | -15% | -$400,451 | ||||||
2026-05-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $63.48 | -1,625 | 38,498 | -4% | -$103,155 | ||||||
| D | 2026-05-04 | SRZN | Surrozen, Inc./De | Li Yang | Exec. VP, Research | S - Sale+OE | $33.33 | -1,584 | 17,918 | -8% | -$52,799 | |||||
| D | 2026-05-04 | SRZN | Surrozen, Inc./De | Williams Charles O | COO | S - Sale+OE | $33.33 | -2,036 | 16,571 | -11% | -$67,866 | |||||
| D | 2026-05-04 | SRZN | Surrozen, Inc./De | Parker Craig C | CEO | S - Sale+OE | $33.33 | -4,524 | 16,553 | -21% | -$150,798 | |||||
2026-05-01 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $18.92 | -5,467 | 600,004 | -1% | -$103,447 | ||||||
2026-05-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $82.04 | -2,000 | 173,371 | -1% | -$164,080 | ||||||
| D | 2026-05-01 | MRNA | Moderna, Inc. | Hussain Abbas | Dir | S - Sale+OE | $46.63 | -5,682 | 12,066 | -32% | -$264,952 | |||||
2026-05-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $10.05 | -22,000 | 1,078,391 | -2% | -$221,025 | ||||||
2026-05-01 | IMVT | Immunovant, Inc. | Susman Robert Graham | Dir | S - Sale | $27.17 | -2,502 | 36,394 | -6% | -$67,979 | ||||||
2026-05-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $56.83 | -2,250 | 160,744 | -1% | -$127,870 | ||||||
| D | 2026-05-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $6.47 | -10,781 | 121,451 | -8% | -$69,753 | |||||
| D | 2026-04-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $25.37 | -7,500 | 10,503 | -42% | -$190,299 | |||||
2026-04-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $14.79 | -972 | 212,895 | 0% | -$14,376 | ||||||
2026-04-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $14.79 | -753 | 275,857 | 0% | -$11,137 | ||||||
2026-04-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $14.79 | -1,490 | 418,557 | 0% | -$22,037 | ||||||
| A | 2026-04-29 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $1.89 | +15,000 | 397,500 | +4% | +$28,350 | |||||
| A | 2026-04-29 | CMPX | Compass Therapeutics, Inc. | Anderman Jonathan | GC | P - Purchase | $1.89 | +25,000 | 196,000 | +15% | +$47,250 | |||||
| M | 2025-09-11 | ESLA | Estrella Immunopharma, Inc. | Xu Jiandong | CFO | P - Purchase | $1.24 | +2,100 | 282,188 | +1% | +$2,594 | |||||
2026-04-29 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.11 | +5,000 | 280,766 | +2% | +$5,550 | ||||||
| D | 2026-04-27 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.23 | -19,037 | 377,802 | -5% | -$270,897 | |||||
2026-04-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $129.16 | -10,000 | 632,567 | -2% | -$1,291,608 | ||||||
| D | 2026-04-27 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $132.41 | -3,120 | 54,400 | -5% | -$413,129 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |